Autosomal Dominant Hyperinsulinism Due to Sulfonylurea Receptor-1 (SUR1/ABCC8) Deficiency

Autosomal Dominant Hyperinsulinism Due to Sulfonylurea Receptor-1 (SUR1/ABCC8) Deficiency is a rare genetic condition where the pancreas releases too much insulin even when blood sugar is low. SUR1 is one half of the KATP channel (the “glucose brake”) on beta cells; when SUR1 is faulty, the brake fails and insulin keeps coming, causing recurrent hypoglycemia from infancy through childhood and sometimes into adulthood. The autosomal dominant form is often milder than recessive KATP disease and can present later, but it still carries a risk of seizures and brain injury if untreated. NCBI+2Frontiers+2

Autosomal dominant hyperinsulinism from ABCC8 (SUR1) variants is a genetic condition where the pancreatic β-cells release too much insulin even when blood sugar is low, causing repeated hypoglycemia. ABCC8 encodes the sulfonylurea receptor-1 part of the KATP channel (the cell’s “glucose brake”). When dominant loss-of-function variants weaken this channel, β-cells depolarize and secrete insulin inappropriately. Compared with the classic severe, recessive forms, dominant ABCC8 disease is often milder and frequently responds to diazoxide, though severity varies among families. NCBI+2Orpha+2

In children with KATP-channel hyperinsulinism, the two main genes are ABCC8 (SUR1) and KCNJ11 (Kir6.2). Inactivation of this channel explains the pathophysiology: with the channel closed, calcium floods in and insulin is secreted regardless of glucose level. Recessive inactivating variants usually cause severe, diffuse, diazoxide-unresponsive disease; dominant ABCC8 variants more often produce diazoxide-responsive hypoglycemia that is diffuse (not focal). NCBI+2jcrpe.org+2

Other names

Doctors may also call this condition: Congenital Hyperinsulinism (CHI) due to ABCC8 mutation; KATP-HI; SUR1-HI; autosomal dominant hyperinsulinism (AD-HI); or “KATP channel–related HI.” All of these refer to excessive insulin secretion caused by disease-causing variants in ABCC8 (SUR1). NCBI+2MedlinePlus+2

Types

Clinically, HI is grouped by pattern in the pancreas: focal (a small insulin-overactive patch), diffuse (all beta cells over-secrete), and atypical (mixed areas). Autosomal dominant SUR1-HI is more often diffuse and milder/later-onset than the severe neonatal recessive forms; some dominant cases respond to medicines like diazoxide. 18F-DOPA PET helps find focal lesions when suspected; focal disease can be cured by limited surgery. PMC+2PubMed+2

---

Causes

1. Missense variants that reduce SUR1 function. Single-letter DNA changes can alter SUR1 structure so the KATP channel won’t open properly; the beta cell can’t sense low sugar and keeps releasing insulin. MedlinePlus+1

2. Trafficking defects. Some ABCC8 mutations make SUR1 that cannot reach the cell surface; channels remain inside the cell, so the brake is absent. PMC

3. Nucleotide-binding (NBD) domain defects. Changes in SUR1’s ATP/ADP-handling domains block the normal open-close cycle of the channel. OUP Academic

4. Dominant-negative effects. In autosomal dominant HI, the mutant SUR1 can “poison” the channel complex and impair even the normal partner copy, leading to disease with just one bad allele. OUP Academic

5. Altered MgADP activation. SUR1 normally helps MgADP open the channel during low fuel states; mutations blunt this response so insulin does not switch off. Frontiers

6. Abnormal sulfonylurea binding/gating. SUR1 is the target of sulfonylureas; pathogenic changes can distort gating behavior independent of drug exposure, sustaining insulin release. Frontiers

7. Partial loss of channel expression. Some variants reduce the number of channels at the membrane, lowering the cell’s ability to stop insulin release during fasting. PMC

8. Temperature-sensitive folding problems. Certain SUR1 changes misfold at body temperature and degrade, again reducing functional channels. PMC

9. Exon-level deletions/duplications. Larger ABCC8 copy-number variants can impair SUR1 and cause HI. NCBI

10. Post-natal stressors revealing a mild genotype. Illness, poor intake, or prolonged fasting can “unmask” hypoglycemia in milder, autosomal dominant forms. PMC

11. High carbohydrate load with hyperinsulinemic response. After high-carb feeds, impaired channel braking exaggerates insulin spikes and post-prandial lows. NCBI

12. Exercise-related lows. Activity uses glucose; with poor counter-regulation (still-high insulin), glucose can fall quickly. PMC

13. Nocturnal/fasting vulnerability. Overnight fasting stresses the system; without ketones and free fatty acids (suppressed by insulin), the brain has no backup fuel. Pediatric Endocrine Society

14. Intercurrent infections. Sickness reduces intake and increases needs; persistent insulin secretion puts patients at risk of severe hypoglycemia. PMC

15. Medication interactions (e.g., sulfonylureas). Exposure can further close KATP channels and worsen lows in susceptible patients. Pediatric Endocrine Society

16. Developmental beta-cell hyperfunction in infancy. Early life has active beta cells; with a faulty brake, neonatal hypoglycemia is common. NCBI

17. Dominant mosaicism. A parent with low-level mosaicism may appear unaffected but transmit a pathogenic ABCC8 variant causing child-onset HI. NCBI

18. Glycemic stress after prolonged fasting tests. During diagnostic fasts, the defective channel prevents physiologic insulin suppression, confirming the mechanism. Pediatric Endocrine Society

19. Reduced ketogenesis. Inappropriately high insulin suppresses lipolysis and ketone formation, removing brain “backup fuel,” increasing symptomatic risk. Pediatric Endocrine Society

20. Progressive beta-cell dysfunction with age (subset). Some dominant ABCC8 carriers later show glucose intolerance or diabetes after years of dysregulated KATP signaling. PMC

---

Symptoms

1. Jitteriness or tremor. Low glucose triggers adrenaline, causing shakiness, especially in infants. NCBI

2. Sweating and pallor. Autonomic activation during lows leads to clammy skin and paleness. NCBI

3. Irritability or unusual crying. The brain is sensitive to low sugar; mood and behavior can change quickly. NCBI

4. Poor feeding or vomiting. Babies may refuse feeds during hypoglycemia or vomit after attempts. NCBI

5. Lethargy or sleepiness. The brain lacks fuel and slows down; children seem drowsy or “out of it.” NCBI

6. Seizures. Severe or prolonged lows can cause convulsions; this is an emergency. NCBI

7. Apnea or breathing pauses (neonates). Very low sugar may suppress normal breathing patterns. NCBI

8. Cyanosis (blue lips/skin) during events. Reflects respiratory instability or poor perfusion during severe episodes. NCBI

9. Headache (older children). Post-hypoglycemia, children may complain of headache and fatigue. Pediatrics

10. Confusion or poor concentration. Brain function dips when glucose is low; school performance may fluctuate. Pediatrics

11. Large birth weight (macrosomia) in some. In-utero high insulin can promote growth; not universal in AD forms. NCBI

12. Developmental delays if lows were severe/recurrent. Repeated hypoglycemia can injure the brain if not promptly treated. Pediatrics

13. Visual or behavioral changes during lows. Blurring, staring spells, or sudden quietness can signal hypoglycemia. Pediatrics

14. Nocturnal awakenings/nightmares. Overnight lows can disturb sleep or cause early morning irritability. Pediatric Endocrine Society

15. Dizziness or faintness with exercise/fasting. Symptoms can appear with longer gaps between meals or activity. PMC

---

Diagnostic tests

A) Physical exam

1. General examination during and after a low. Doctors look for sweating, pallor, tremor, or poor tone and check recovery once glucose is corrected—this helps link symptoms to hypoglycemia. Pediatric Endocrine Society

2. Growth and nutrition assessment. Weight/length/head size and feeding patterns show the impact of repeated lows and guide support. Pediatrics

3. Neurologic check. Tone, reflexes, and alertness help spot seizure risk or injury from past severe episodes. Pediatrics

4. Cardiorespiratory observation in infants. Heart rate, breathing, and oxygenation may fluctuate during severe hypoglycemia and must be monitored. Pediatrics

5. Signs of dehydration or intercurrent illness. Illness can precipitate lows; exam findings change the care plan. PMC

B) “Manual” bedside/functional tests

6. Frequent glucose checks (plasma preferred). Capillary meters help screen, but lab plasma glucose confirms true hypoglycemia because meters are less accurate at low ranges. Pediatric Endocrine Society

7. Supervised diagnostic fast. In hospital, a carefully timed fast shows whether glucose falls with inadequate ketones/FFAs (a hallmark of HI) and captures the “critical sample.” Pediatric Endocrine Society

8. Glucagon stimulation during a low. A quick glucagon dose that rapidly raises glucose suggests insulin was suppressing liver glucose release—supporting HI. Pediatric Endocrine Society

9. Diazoxide trial (when appropriate). Response to diazoxide (a KATP opener) suggests KATP-related HI may be medically managed; lack of response raises concern for severe KATP defects or focal disease. OUP Academic

10. Feeding challenge/avoidance of prolonged fasting. Observing glucose trends across feeds, overnight, and with activity helps tailor prevention plans and confirms triggers. Pediatrics

C) Laboratory & pathological tests

11. Critical sample during hypoglycemia. When plasma glucose is low, blood is drawn for insulin, C-peptide, proinsulin, beta-hydroxybutyrate (BOHB), free fatty acids (FFA), and lactate. HI typically shows inappropriately detectable insulin, suppressed ketones (low BOHB), and low FFAs. Pediatric Endocrine Society

12. Counter-regulatory hormones. Cortisol and growth hormone are checked to exclude hormonal deficiencies that can mimic or worsen hypoglycemia. Pediatric Endocrine Society

13. Ammonia level. Elevated ammonia suggests HI/HA (GLUD1) rather than ABCC8 disease; normal ammonia supports SUR1-HI when combined with other findings. Frontiers

14. Genetic testing of ABCC8 (and KCNJ11). Sequencing and copy-number analysis find pathogenic variants confirming SUR1-HI and help decide on imaging and family counseling. NCBI

15. Expanded HI gene panel when needed. If ABCC8/KCNJ11 are negative, panels include other HI genes (e.g., GCK, GLUD1, HADH, SLC16A1, UCP2, HNF1A/4A, HK1) to refine diagnosis. Frontiers

16. Proinsulin/insulin ratio. An inappropriately high proinsulin and measurable insulin during hypoglycemia support endogenous hyperinsulinism rather than surreptitious insulin use. Pediatric Endocrine Society

17. Pathology of resected tissue (rarely needed in AD-HI). When surgery is done for suspected focal disease, histology classifies focal vs diffuse vs atypical HI. PubMed

D) Electrodiagnostic tests

18. EEG (electroencephalogram). Used if seizures occur or are suspected; helps assess hypoglycemic encephalopathy and guides anti-seizure care while HI is controlled. Pediatrics

19. Continuous cardiorespiratory/oximetry monitoring in infants. Detects apnea/bradycardia during severe lows in the neonatal period; supports safe inpatient fasting studies. Pediatrics

20. Optional evoked-response studies in selected cases. If prolonged severe hypoglycemia caused suspected sensory pathway injury, clinicians may add visual or auditory evoked potentials to assess function. Pediatrics

E) Imaging tests (how we localize disease)

1. 18F-DOPA PET/CT is the test of choice for finding a focal pancreatic lesion in diazoxide-unresponsive HI; it guides curative limited surgery. Its accuracy depends on reader expertise and very small lesions can be missed, so a negative scan does not fully exclude focal HI. Journal of Nuclear Medicine+2PubMed+2
2. MRI/CT/ultrasound of the pancreas are less sensitive than 18F-DOPA PET for focal lesions but may be used when PET is unavailable or to plan surgery; results must be interpreted with the genetic picture. PMC
3. Brain MRI may be considered after severe hypoglycemia to assess injury and support neurodevelopmental planning; it does not diagnose HI but guides rehabilitation after events. Pediatrics

Non-pharmacological treatments

Note: These are supportive, gene-agnostic measures used in CHI (including dominant ABCC8) to keep glucose safe while drugs and genetics are sorted out.

1. Rapid IV dextrose bolus and infusion.
   Description: In symptomatic or severe hypoglycemia, give a weight-based dextrose bolus followed by a continuous glucose infusion through a secure IV. Purpose: Restore plasma glucose above the safety threshold and prevent seizures or brain injury. Mechanism: Exogenous glucose immediately raises blood sugar independent of insulin. PMC+1

2. Avoid fasting; feed frequently, including overnight.
   Description: Small, frequent breast/formula feeds or continuous overnight enteral feeds. Purpose: Prevent long gaps that precipitate hypoglycemia. Mechanism: Provides steady carbohydrate input while endogenous insulin is inappropriately high. PMC

3. Higher-calorie feeds (under dietitian guidance).
   Description: Increase caloric density safely with dietetic oversight. Purpose: Reduce the total volume needed and support growth while maintaining euglycemia. Mechanism: More calories per mL blunt hypoglycemic dips between feeds. PMC

4. Continuous enteral feeding (NG/PEG) when needed.
   Description: Use a nasogastric tube or gastrostomy for continuous or nocturnal feeds. Purpose: Stabilize glucose in infants who drop overnight or during illness. Mechanism: Continuous carbohydrate delivery offsets insulin-driven glucose uptake. PMC

5. Emergency glucagon rescue plan at home.
   Description: Families are trained to give IM/subcutaneous glucagon for severe symptomatic lows. Purpose: Immediate home rescue while arranging medical care. Mechanism: Glucagon mobilizes hepatic glycogen to raise plasma glucose. (Glucagon is FDA-labeled for severe hypoglycemia.) FDA Access Data+1

6. Illness (“sick-day”) protocol.
   Description: Lower thresholds to check glucose more often; earlier use of supplemental feeds/IV dextrose. Purpose: Prevent hypoglycemia during reduced intake or intercurrent illness. Mechanism: Anticipates higher insulin sensitivity and reduced intake. PMC

7. Thermoregulation and prompt treatment of infection.
   Description: Keep infants warm, treat infections quickly. Purpose: Reduce catabolic stress that destabilizes glucose control. Mechanism: Minimizes stress-induced hypoglycemia in infants with limited reserves. PMC

8. Multidisciplinary HI center involvement.
   Description: Early referral to experienced CHI centers for coordinated care. Purpose: Optimize genetics, imaging, and individualized plans. Mechanism: Centers apply guideline-driven pathways and advanced imaging/surgery when needed. Children’s Hospital of Philadelphia+1

9. Parent education and home glucometer/CGM use (where appropriate).
   Description: Teach recognition of hypoglycemia signs and proper glucose checking. Purpose: Early detection and rapid correction at home. Mechanism: Monitoring guides feeding or rescue interventions before symptoms worsen. PMC

10. Peri-procedural glucose planning.
    Description: For vaccinations or procedures, plan feeds/IV dextrose and monitoring. Purpose: Prevent fasting-related hypoglycemia. Mechanism: Maintain glucose input when oral intake is interrupted. PMC

11. Genetic counseling for the family.
    Description: Explain autosomal dominant inheritance and recurrence risk. Purpose: Inform future pregnancy planning and early newborn screening in siblings. Mechanism: Early identification enables prompt treatment, reducing neuroglycopenic risk. NCBI

12. Neurodevelopmental follow-up.
    Description: Structured developmental assessments and early interventions. Purpose: Detect and address sequelae of early hypoglycemia. Mechanism: Neuroplastic support after potential hypoglycemic brain stress. PMC

13. Targeted use of central venous access when IV glucose needs are high.
    Description: Use a central line if high-concentration dextrose is necessary. Purpose: Deliver adequate glucose safely when peripheral lines fail. Mechanism: Central veins tolerate higher osmolar infusions. Children’s Hospital of Philadelphia

14. Standardized hospital hypoglycemia pathways.
    Description: Adopt stepwise hospital algorithms for work-up and stabilization. Purpose: Reduce delays and variability. Mechanism: Evidence-guided escalation from feeds to IV glucose to meds. Children’s Hospital of Philadelphia

15. Early endocrine consultation.
    Description: Involve pediatric endocrinology at presentation. Purpose: Speed diagnostic sampling (“critical labs”) and gene testing. Mechanism: Captures insulin, C-peptide, β-hydroxybutyrate at the time of hypoglycemia. PMC

16. Use of 18F-DOPA PET when focal disease is suspected.
    Description: Functional PET to localize focal lesions. Purpose: Identify surgically curable focal forms; confirm diffuse disease. Mechanism: 18F-DOPA uptake highlights hyperfunctioning β-cell clusters. PMC+1

17. Written emergency plan for schools/caregivers.
    Description: Simple action plan with thresholds and rescue steps. Purpose: Keep non-medical caregivers aligned on safety. Mechanism: Reduces response time to hypoglycemia. PMC

18. Pre-discharge trial of overnight routine.
    Description: Simulate the home night schedule under supervision. Purpose: Confirm that the plan prevents nocturnal lows. Mechanism: Adjusts feeds/meds before discharge. Children’s Hospital of Philadelphia

19. Transition planning to later childhood/adolescence.
    Description: Update diet/activity guidance as fasting tolerance improves. Purpose: Sustain safety as physiology and lifestyle change. Mechanism: Periodic reassessment of targets and rescue tools. PMC

20. Family psychosocial support.
    Description: Access to counseling and peer support groups. Purpose: Reduce caregiver stress and improve adherence. Mechanism: Better coping leads to more consistent monitoring/feeding. Congenital Hyperinsulinism International

Drug treatments

Important safety note: For CHI due to dominant ABCC8, diazoxide is the first-line medication and is often effective. Many other medicines below are off-label for CHI; I state this clearly and cite both the FDA label (drug facts) and peer-reviewed HI sources (clinical use/risks). FDA Access Data+2PMC+2

1. Diazoxide (PROGLYCEM®) — first-line; often effective in dominant ABCC8
   Class: KATP channel opener. Dosage/Time: Pediatric dosing is individualized; label provides general dosing for hyperinsulinism—clinicians titrate to effect with careful monitoring for fluid retention and blood pressure. Purpose: Reduce insulin secretion to prevent hypoglycemia. Mechanism: Opens β-cell KATP channels, hyperpolarizing the cell and suppressing insulin release. Side effects: Fluid retention, edema, hypertrichosis, potential pulmonary hypertension in neonates—FDA has warned about a serious lung condition in infants; monitor closely. Evidence: Only FDA-approved drug in the U.S. for hyperinsulinemic hypoglycemia; dominant ABCC8 disease is frequently diazoxide-responsive. Orpha+3FDA Access Data+3U.S. Food and Drug Administration+3

2. Octreotide (Sandostatin®) — off-label for CHI
   Class: Somatostatin analogue. Dosage/Time: Typically 5–10 µg/kg/day SC in divided doses or continuous SC infusion, titrating to ~20 µg/kg/day per CHI resources; long-acting depot exists. Purpose: Second-line when diazoxide is insufficient or contraindicated. Mechanism: Inhibits insulin secretion via somatostatin receptors. Side effects: GI upset, gallstones, glucose dysregulation, bradycardia; pediatric safety data exist but it’s not FDA-approved for CHI. Congenital Hyperinsulinism International+3FDA Access Data+3FDA Access Data+3

3. Lanreotide (Somatuline® Depot) — off-label for CHI
   Class: Long-acting somatostatin analogue. Dosage/Time: Deep SC injection every 4 weeks (per label for approved indications); occasional off-label pediatric use in CHI centers when octreotide is not suitable. Purpose: Reduce insulin secretion and smooth glucose profiles. Mechanism: Somatostatin receptor agonism. Side effects: Similar to octreotide (GI, gallbladder issues, glucose shifts). FDA Access Data

4. Glucagon for injection — rescue & short-term stabilization
   Class: Antihypoglycemic hormone. Dosage/Time: IM/SC/IV emergency dosing per label for severe hypoglycemia; infusions may be used in hospital to raise glucose while other therapies are optimized. Purpose: Acute correction of severe hypoglycemia. Mechanism: Mobilizes hepatic glycogen; transient effect. Side effects: Nausea, vomiting; ineffective if glycogen stores are depleted. FDA Access Data+1

5. Sirolimus (Rapamune®) — off-label; reserve for refractory cases
   Class: mTOR inhibitor immunosuppressant. Dosage/Time: Careful dosing to target trough levels under specialist supervision. Purpose: Consider only in severe, medically/surgically refractory CHI after detailed risk–benefit discussion. Mechanism: mTOR pathway inhibition may reduce β-cell insulin secretion/proliferation. Side effects: Mucositis, infections, dyslipidemia, liver enzyme elevation, pneumonitis; serious events reported—multiple experts urge extreme caution in infants. BioMed Central+3FDA Access Data+3New England Journal of Medicine+3

6. Thiazide diuretic (e.g., hydrochlorothiazide) — adjunct to diazoxide
   Class: Thiazide diuretic. Dosage/Time: Dose per pediatric diuretic practice. Purpose: Manage diazoxide-induced fluid retention/edema; not an anti-hypoglycemia drug by itself. Mechanism: Promotes diuresis to counter fluid retention. Side effects: Electrolyte loss (hypokalemia), dehydration—monitor closely. FDA Access Data

7. Long-acting octreotide (LAR depot) — off-label maintenance
   Class: Somatostatin analogue depot. Dosage/Time: IM every 4 weeks per label (for approved conditions); used off-label by HI centers to reduce injection burden in selected children. Purpose/Mechanism/Side effects: As for octreotide above. FDA Access Data

8. Dextrose (IV infusion) — bridge therapy (hospital)
   Class: Carbohydrate solution. Dosage/Time: Concentration and rate individualized to maintain glucose; central access may be required for high concentrations. Purpose: Stabilize glucose until definitive therapy works. Mechanism: Directly supplies glucose. Side effects: Line complications, electrolyte shifts. Children’s Hospital of Philadelphia

9. Acarbose — rare adjunct; off-label
   Class: α-glucosidase inhibitor. Dosage/Time: Oral; titrate to GI tolerance in older children with post-prandial dips. Purpose: Slow carb absorption to blunt swings. Mechanism: Delays intestinal carbohydrate breakdown. Side effects: Flatulence, diarrhea; evidence limited in CHI. PMC

10. Nifedipine — generally not effective; rarely used
    Class: Calcium channel blocker. Note: Early case reports exist, but systematic experience shows poor efficacy in CHI; not recommended in guidelines. Purpose/Mechanism: Theoretical calcium-influx reduction in β-cells. Side effects: Hypotension, flushing; avoid routine use. PMC

11. Pasireotide — off-label; very limited use
    Class: Somatostatin analogue with SSTR5 affinity. Note: Risk of hyperglycemia is high in approved uses (e.g., Cushing’s). May paradoxically worsen glycemia profiles; not standard for CHI. PMC

12. Everolimus — off-label, similar cautions as sirolimus
    Class: mTOR inhibitor. Purpose/Mechanism: Same pathway as sirolimus; occasional case reports. Side effects: Immunosuppression, mucositis, infections; not routine for infants. OUP Academic

13. Hydrochlorothiazide + diazoxide (combination) — adjunct
    Description: Used when edema limits diazoxide dosing, to allow continuation of the proven first-line agent. Mechanism/Side effects: See items 1 and 6. FDA Access Data+1

14. Glucose-polymer supplements (hospital use) — dietary/medical bridge
    Description: Concentrated complex carbohydrate solutions under supervision. Purpose: Reduce IV needs once stable. Evidence: Supportive in pathways; not a primary anti-insulin medicine. Children’s Hospital of Philadelphia

15. Long-acting glucagon analogs (investigational) — research context only
    Note: Not FDA-approved for CHI; included for completeness as research evolves. Use: Clinical trials only. PMC

Not recommended/insufficient evidence (for CHI): insulin secretagogue antagonists beyond diazoxide, routine calcium-channel blockers, growth-hormone therapy, corticosteroids, or SGLT inhibitors. Reason: Lack of efficacy or unfavorable risk in infants with CHI; not in guidelines. PMC

If you prefer, I can expand any of the off-label items into 150-word monographs with dosing ranges used by HI centers, but I’ve prioritized safety and accuracy here.

Dietary molecular supplements

For congenital hyperinsulinism, there are no dietary supplements proven to correct the underlying insulin dysregulation in ABCC8 disease. Unlike glycogen storage disorders (where uncooked cornstarch helps), supplements have not shown reliable benefit in CHI and could delay effective care. Families should avoid unproven “glucose boosters” or herbal products and instead use a dietitian-guided feeding plan integrated with medical therapy. PMC

Because your brief asked for “10 supplements with dose and mechanism,” I want to be transparent: providing such a list would be misleading for CHI and not supported by peer-reviewed guidance. Safe, evidence-based management relies on feeding strategy + diazoxide (often), and specialist therapies where needed. PMC+1

Immunity-booster / regenerative / stem-cell drugs

There are no FDA-approved immune boosters, regenerative, or stem-cell drugs for CHI. Using immunosuppressants like sirolimus is sometimes considered in extreme, refractory cases to reduce insulin secretion, not to “boost immunity,” and it carries substantial risks in infants. Stem-cell therapies are not established for CHI. Any claim otherwise would be unsafe. FDA Access Data+1

Surgeries

1) Lesionectomy or limited pancreatectomy for focal CHI.
What: Surgical removal of a focal β-cell adenomatous area. Why: Focal disease can be curative if precisely localized by 18F-DOPA PET and confirmed intra-operatively. PMC

2) Near-total pancreatectomy for diffuse, medically refractory CHI.
What: Remove ~95–98% of pancreas in specialized centers. Why: Last resort when hypoglycemia persists despite maximal medical therapy; reduces insulin output but increases long-term diabetes risk. PMC

3) Intra-operative pancreatic ultrasound and frozen-section mapping.
What: Imaging and pathology during surgery. Why: Define surgical margins and avoid excessive resection in focal disease. PMC

4) Central venous access placement (supportive).
What: Long-term line for high-concentration dextrose or medications during stabilization. Why: Maintain safe glucose while awaiting genetics, imaging, or response to therapy. Children’s Hospital of Philadelphia

5) Gastrostomy tube placement.
What: PEG/G-tube to permit continuous or nocturnal feeding. Why: Prevents recurrent hypoglycemia in infants needing sustained carbohydrate delivery. PMC

Preventions

1. You can’t prevent the gene, but you can reduce harm by early recognition of neonatal hypoglycemia and prompt endocrine evaluation. PMC

2. Genetic counseling for families with known ABCC8 variants to plan early monitoring in future pregnancies/siblings. NCBI

3. Birth-plan alerts for known at-risk infants so glucose monitoring starts immediately after delivery. PMC

4. Avoid prolonged fasting, especially overnight in infants. PMC

5. Have rescue glucagon available and teach caregivers to use it. FDA Access Data

6. Illness plans: increase monitoring/feeds during infections. PMC

7. Regular growth and neurodevelopment checks to detect consequences early. PMC

8. Medication safety monitoring (BP, fluid status for diazoxide; gallbladder/glucose for somatostatin analogues; labs and infection vigilance for sirolimus if ever used). FDA Access Data+2FDA Access Data+2

9. Use HI-center protocols for hospitalizations and procedures. Children’s Hospital of Philadelphia

10. Family education and written emergency plans for home/school. PMC

When to see a doctor urgently

Seek urgent care if the child has seizure, lethargy, poor feeding, vomiting, unusual sweating, pallor, irritability, or unresponsiveness, or if home glucose is below your clinician’s safety threshold despite extra feeding. These signs reflect neuroglycopenia and need immediate correction and medical evaluation. PMC

What to eat and what to avoid

Eat/Do: frequent feeds; balanced meals with complex carbohydrates and adequate protein/fat (dietitian-guided); consider continuous nocturnal feeds if prescribed; keep an oral fast-acting carbohydrate handy for mild lows; follow the individualized feeding plan from your HI team. PMC

Avoid/Be cautious: prolonged fasting; skipping meals; unproven supplements; and (in older children/teens) alcohol or extreme endurance exercise without a prevention plan. Avoid changing feeds/meds without your HI team’s advice. PMC

FAQs

1) What makes dominant ABCC8 hyperinsulinism “dominant”?
A single pathogenic ABCC8 variant can cause disease and be passed from an affected parent to a child with a 50% chance each pregnancy. NCBI

2) How is it different from recessive ABCC8 disease?
Recessive forms are usually severe and diazoxide-unresponsive; dominant forms are often milder and diazoxide-responsive, though there’s variability. NCBI+1

3) Why does diazoxide often work here?
It opens KATP channels; many dominant ABCC8 channels retain enough function to respond, restoring the β-cell “glucose brake.” FDA Access Data

4) Is octreotide safe for infants?
It’s widely used off-label when diazoxide is inadequate, with careful monitoring for GI, gallbladder, and glucose effects. PMC

5) Should we use sirolimus early?
Generally no. Reserve for refractory cases after expert consultation because of immunosuppression and serious adverse events. BioMed Central+1

6) When is surgery considered?
If imaging suggests a focal lesion (curable by lesionectomy) or if diffuse disease remains refractory to optimal medical therapy. PMC+1

7) Does every child need 18F-DOPA PET?
Not always. It’s most valuable when a focal lesion is suspected. Dominant ABCC8 disease is usually diffuse. PMC

8) Can this go away?
Some children improve with age, especially milder dominant forms; others need long-term plans. Ongoing follow-up is essential. PMC

9) Could diabetes appear later in life?
Some ABCC8/KCNJ11 variants are linked with later glucose intolerance or diabetes; families should have periodic reassessment. Endotext+1

10) Are “superfoods” or vitamins helpful?
No supplement has proven benefit for CHI; stick to dietitian-guided feeding and prescribed medicines. PMC

11) What monitoring is needed on diazoxide?
Watch fluid status, blood pressure, and consider echocardiography if concerns; heed the FDA pulmonary hypertension warning in neonates. FDA Access Data+1

12) How do somatostatin analogs affect glucose?
They can lower insulin but also alter other hormones, sometimes causing hyperglycemia; dose carefully. FDA Access Data

13) Does exercise matter?
Normal play is encouraged; avoid prolonged fasting before activity and carry fast carbs for symptoms. PMC

14) Who should oversee care?
A pediatric endocrinologist and, when available, a specialized Congenital HI center with genetics, imaging, surgery, and dietetics. Children’s Hospital of Philadelphia

15) Where can clinicians find structured guidance?
See the international guidelines and comprehensive reviews linked below. PMC+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 02, 2025.